Updated hourlyHourly refreshMon, Sep 21, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare
CAMBRIDGE, Mass., September 14, 2026--Lysoway Therapeutics, a clinical-stage biotechnology company pioneering therapeutics targeting lysosomal ion channels for age-related neurodegenerative diseases, today announced the publication of preclinical data evaluating its lead candidate, LW-1017, in Scientific Reports, a journal from Nature Portfolio.
Sep 14 · 11:00·mlpr-businesswire
Healthcare · Retail
WPC80 whey pricing has increased more than fivefold since 2023, reaching approximately US$14.50/lb in 2026Rejuvenate remains US$24.99 for 14 servings and US$39.99 for 30 servings at U.S. retail — as much as 40% lower per serving than a current leading 2-lb whey benchmarkPublished human research supports the ability of a low-dose leucine-rich essential amino acid formulation to stimulate muscle protein synthesis comparably to 20g of whey proteinRejuvenate is available in approximately 6,800 CVS...
Sep 14 · 11:00·mlpr-newsfile
Healthcare
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and...
Sep 14 · 10:59·PR Newswire
Healthcare
First-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medications, and increasingly complex fulfilment needs FRANKLIN LAKES, N.J., Sept. 14, 2026...
Sep 14 · 10:50·PR Newswire
Finance · Healthcare
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the...
Sep 14 · 10:45·PR Newswire
Finance · Healthcare
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18 F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).
Sep 14 · 10:30·GlobeNewswire
Healthcare
First-in-human study in British Journal of Urology International confirms bladder cancer treatment can shift from the operating room to the outpatient clinic-enabling complete treatment and diagnostic sampling in minutes on awake patients. GOTHENBURG, Sweden, Sept. 14, 2026 /PRNewswire/...
Sep 14 · 10:30·PR Newswire
Finance · Healthcare
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
Sep 14 · 10:16·GlobeNewswire
Finance · Healthcare
CHICAGO, September 14, 2026--Artisight, the leader in Smart Hospital technology, acquired TMG Global, a technology services firm with deep expertise in healthcare infrastructure, site readiness, and large-scale technology deployments. The acquisition strengthens Artisight’s ability to integrate smart hospital technology across complex clinical environments in leading U.S. hospitals.
Sep 14 · 10:00·mlpr-businesswire
Healthcare
NEW YORK, September 14, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 56,650 common shares of the Company (the "Options") with effective grant dates of September 1
Sep 14 · 10:00·mlpr-businesswire
Healthcare
Research Highlights: Increasing pulse pressure (the gap between the upper and lower numbers in blood pressure readings), long attributed to falling estrogen levels caused by menopause, begins about two decades before women enter menopause, according to an analysis from the large and multi-generation Framingham Heart Study. The study suggests that healthcare professionals should pay greater attention to women with a wide (higher number) pulse pressure because it is a sign that the body’s largest blood vessel (the aorta) is becoming stiffer and less flexible, therefore, increasing the risk of heart disease. Wide pulse pressure is a major risk factor for cardiovascular disease, dementia and kidney disease and may make high blood pressure less responsive to some medication treatments. DALLAS -
Sep 14 · 09:00·NewMediaWire
Finance · Healthcare
MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial ( NCT05671510 ) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.
Sep 14 · 08:00·GlobeNewswire